Application of indolepropionic acid in prevention and treatment of drug-induced liver injury
By using indolepropionic acid or its derivatives, the problem of drug-induced liver injury treatment is solved, and the progress of liver failure and mortality rate of liver injury is achieved, providing a safe and effective treatment plan.
Patent Information
- Application Number
- CN202411176464.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-29
AI Technical Summary
The lack of effective drugs in the prior art for the prevention and treatment of drug-induced liver injury has resulted in the reliance on supportive treatment and liver transplantation, which is limited by high costs and donor scarcity.
Using indole propionic acid or a pharmaceutically acceptable salt or derivative thereof as an active ingredient for the preparation of drugs or pharmaceutical compositions for the prevention and/or treatment of drug-induced liver injury, reduces AST and ALT levels in the liver by reducing AST and ALT levels in the liver The levels of liver cell apoptosis and inflammatory factors inhibit the production of NLRP3 inflammasomes and reduce hepatitis infiltration and necrosis.
Effectively prevent and treat drug-induced liver injury, reduce the progress of liver failure, significantly reduce the mortality rate of liver injury induced by acetaminophen and other drugs, and reduce liver inflammation and necrosis, providing a safe and effective treatment plan.
Smart Images

Figure SMS_1 
Figure SMS_3 
Figure SMS_4
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and specifically to the application of indolepropionic acid (IPA) in preventing and treating drug-induced liver injury. Background Art
[0002] A variety of immune and metabolic diseases can present as acute liver failure, but the major trigger of liver failure is drug-induced liver injury, which is characterized by a rapid deterioration of liver function. In patients without previous liver disease, drug-induced liver injury leads to altered mental status, coagulopathy, multi-organ failure, and death.
[0003] Due to the lack of clear and effective drugs, the main treatments for drug-induced liver injury are supportive care and liver transplantation, but both treatments are restricted by high costs and uncertain effects. In addition, the scarcity of donors severely limits the application of liver transplantation.
[0004] Therefore, finding suitable therapeutic drugs remains the focus of research on drug-induced liver injury. Summary of the invention
[0005] The object of the present invention is to provide a method for preventing and / or treating drug-induced liver injury.
[0006] Another object of the present invention is to provide a use of indolepropionic acid for treating or preventing drug-induced liver damage.
[0007] The first aspect of the present invention provides a use of an active ingredient, wherein the active ingredient is selected from indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for preparing a drug or a pharmaceutical composition or a kit for preventing and / or treating drug-induced liver injury;
[0008] Wherein, the drug-induced liver injury is caused by drugs selected from the following group: acetaminophen, d-galactosamine, lipopolysaccharide, or a combination thereof.
[0009] In another preferred embodiment, the drug-induced liver injury is caused by drug overdose.
[0010] In another preferred embodiment, the drug-induced liver injury is caused by the side effects of the drug.
[0011] In another preferred embodiment, the drug-induced liver injury includes acute liver injury.
[0012] In another preferred embodiment, the acute liver injury is caused by acetaminophen.
[0013] In another preferred embodiment, for mice, the administration amount of acetaminophen is ≥250 mg / kg, preferably ≥300 mg / kg.
[0014] In another preferred embodiment, for humans, the administration amount of acetaminophen is ≥2.5 g / day, preferably ≥2.8 g / day.
[0015] In another preferred embodiment, the drug-induced liver injury also includes chronic liver injury.
[0016] In another preferred embodiment, the drugs causing drug-induced liver injury further include statins, anti-tuberculosis drugs, traditional Chinese medicine, or a combination thereof.
[0017] In another preferred embodiment, the statin is selected from the following group: atorvastatin, simvastatin, pravastatin, or a combination thereof.
[0018] In another preferred embodiment, the anti-tuberculosis drug is selected from the following group: isoniazid, rifampicin, pyrazinamide, or a combination thereof.
[0019] In another preferred embodiment, the Chinese medicine is selected from the following group: Tripterygium wilfordii, Polygonum multiflorum, or a combination thereof.
[0020] In another preferred embodiment, the drug or pharmaceutical composition or kit is also used for a purpose selected from the following group:
[0021] (y1) reducing the levels of AST and / or ALT in the liver;
[0022] (y2) reduce the level of pro-inflammatory factors;
[0023] (y3) Reduce liver cell apoptosis.
[0024] In another preferred embodiment, the dosage of the drug or pharmaceutical composition or kit is at least 200 mg / kg / d based on the dosage of IPA.
[0025] In another preferred embodiment, the dosage of the drug or pharmaceutical composition or kit is 50-500 mg / kg / day, preferably 80-250 mg / kg / day, for example 200 mg / kg / day, calculated as the dosage of IPA.
[0026] In another preferred embodiment, the dosage of the drug or pharmaceutical composition or kit is 1 to 50 mg / kg / day, preferably 5 to 20 mg / kg / day, for example 8.1 mg / kg / day, calculated as the dosage of IPA.
[0027] In another preferred embodiment, the dosage form of the drug is an oral dosage form.
[0028] In another preferred embodiment, the drug or pharmaceutical composition or kit is administered to a subject selected from the following group: a rodent or a primate.
[0029] In another preferred embodiment, the subject is a subject not on a high-fat diet.
[0030] In another preferred embodiment, the subject is a non-diabetic patient.
[0031] In another preferred embodiment, the object has a feature selected from the following group:
[0032] (c1) the subject is taking ≥300 mg / kg / d of acetaminophen;
[0033] (c2) the subject is administered ≥500 mg / kg / d of d-galactosamine;
[0034] (c3) The subject is administered ≥5 μg / kg / d of lipopolysaccharide.
[0035] In another preferred embodiment, the subject does not suffer from any of the following diseases:
[0036] (x1) Alcoholic fatty liver;
[0037] (x2) Non-alcoholic fatty liver disease.
[0038] In another preferred embodiment, the pharmaceutical composition comprises:
[0039] (z1) a first active ingredient, indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof;
[0040] (z2) optionally, a second active ingredient, other agents for preventing and / or treating drug-induced liver injury; and
[0041] (z3) a pharmaceutically acceptable carrier.
[0042] In another preferred embodiment, in the pharmaceutical composition, the component (z1) accounts for 1-99wt%, preferably 10-90wt%, and more preferably 30-70wt% of the total weight of the pharmaceutical composition.
[0043] In another preferred embodiment, the pharmaceutical composition may contain a single compound or a mixture of multiple compounds.
[0044] In another preferred embodiment, the pharmaceutical composition is used for preparing a method for treating or preventing drug-induced liver injury.
[0045] In another preferred embodiment, the pharmaceutical dosage form is an oral or parenteral dosage form.
[0046] In another preferred embodiment, the oral dosage form is a tablet, powder, granule or capsule, or an emulsion or syrup.
[0047] In another preferred embodiment, the non-oral dosage form is an injection or injection.
[0048] In another preferred embodiment, the pharmaceutical composition is selected from the following group: injection, inhalation, tincture, powder, granule, capsule, oral solution, tablet, pill, suspension, emulsion, lozenge, or pill.
[0049] In another preferred embodiment, the pharmaceutical composition is administered by intravenous injection or intraperitoneal injection.
[0050] In another preferred embodiment, the subject to which the pharmaceutical composition is administered is a human or non-human mammal.
[0051] In another preferred embodiment, the kit comprises:
[0052] (f1) a first pharmaceutical composition comprising (i) indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof as a first active ingredient; and (ii) a pharmaceutically acceptable carrier; and
[0053] (f2) Reagents for detecting inflammatory factors or their mRNA levels.
[0054] In another preferred embodiment, the indolepropionic acid is enteric indolepropionic acid.
[0055] In another preferred embodiment, the indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof is also used for one or more purposes selected from the following group:
[0056] (a1) Reduce the expression levels of TNF, IL-6, Caspase1, IL1β and other RNA in the liver;
[0057] (a2) reduce inflammatory infiltration of the liver;
[0058] (a3) reduce the area of liver necrosis;
[0059] (a4) inhibiting the generation of NLRP3 inflammasome;
[0060] (a5) Reduce the concentration of ALT and / or AST in serum.
[0061] In a second aspect, the present invention provides a medicine kit, comprising:
[0062] (a) a first active ingredient, the first active ingredient comprising indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof; and
[0063] (b) Drugs that cause drug-induced liver injury.
[0064] In another preferred embodiment, the drug causing drug-induced liver injury is selected from the following group: acetaminophen, D-galactosamine, lipopolysaccharide, or a combination thereof.
[0065] In another preferred embodiment, the medicine kit is used to prevent drug-induced liver injury.
[0066] In another preferred embodiment, the drug-induced liver injury is caused by drugs.
[0067] In another preferred embodiment, the drugs that cause drug-induced liver injury also include statins, anti-tuberculosis drugs, traditional Chinese medicine, or a combination thereof.
[0068] In another preferred embodiment, the statin is selected from the following group: atorvastatin, simvastatin, pravastatin, or a combination thereof.
[0069] In another preferred embodiment, the anti-tuberculosis drug is selected from the following group: isoniazid, rifampicin, pyrazinamide, or a combination thereof.
[0070] In another preferred embodiment, the Chinese medicine is selected from the following group: Tripterygium wilfordii, Polygonum multiflorum, or a combination thereof.
[0071] In a third aspect, the present invention provides a method for preventing and / or treating drug-induced liver injury, comprising the steps of:
[0072] A safe and effective amount of indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof is administered to a subject in need thereof.
[0073] In another preferred embodiment, the drug-induced liver injury refers to acute liver injury caused by drug overdose and / or chronic liver injury caused by side effects of drugs.
[0074] In another preferred embodiment, the administration comprises oral administration.
[0075] In another preferred embodiment, the subject includes a human or a non-human mammal.
[0076] In another preferred embodiment, the non-human mammals include rodents and primates, preferably mice, rats, rabbits, and monkeys.
[0077] In another preferred embodiment, the subject is a subject not on a high-fat diet.
[0078] In another preferred embodiment, the subject is a non-diabetic patient.
[0079] In another preferred embodiment, the object has a feature selected from the following group:
[0080] (c1) the subject is taking ≥300 mg / kg / d of acetaminophen;
[0081] (c2) the subject is administered ≥500 mg / kg / d of d-galactosamine;
[0082] (c3) The subject is administered ≥5 μg / kg / d of lipopolysaccharide.
[0083] In another preferred embodiment, the subject does not suffer from any of the following diseases:
[0084] (x1) Alcoholic fatty liver;
[0085] (x2) Non-alcoholic fatty liver disease.
[0086] In another preferred embodiment, the administration frequency of the indolepropionic acid or a pharmaceutically acceptable salt thereof is 1-7 consecutive days per week, preferably 2-5 consecutive days per week, and more preferably 2-3 consecutive days per week.
[0087] In another preferred embodiment, the administration time of the indolepropionic acid or a pharmaceutically acceptable salt thereof is 1-20 weeks, preferably 2-12 weeks, and more preferably 4-8 weeks.
[0088] In another preferred embodiment, the dosage of the indolepropionic acid or a pharmaceutically acceptable salt thereof is 50 to 500 mg / kg / day, preferably 80 to 250 mg / kg / day, for example 200 mg / kg / day.
[0089] In another preferred embodiment, the dosage of indolepropionic acid or a pharmaceutically acceptable salt thereof is 1 to 50 mg / kg / day, preferably 5 to 20 mg / kg / day, for example 8.1 mg / kg / day.
[0090] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0091] Figure 1 The results showed that the serum IPA level in patients with drug-induced liver injury was reduced and negatively correlated with the levels of ALT and AST.
[0092] Figure 2 A gross image of mouse liver showing that prophylactic administration of IPA alleviates acetaminophen-induced drug-induced liver injury in mice.
[0093] Figure 3 It was shown that IPA can effectively reduce the mortality of drug-induced liver injury caused by lethal doses of acetaminophen.
[0094] Figure 4 HE staining images and necrotic area calculations are shown to show that prophylactic use of IPA alleviates drug-induced liver injury in mice induced by acetaminophen and d-galactosamine (GalN) / lipopolysaccharide (LPS).
[0095] Figure 5It was shown that after IPA treatment, serum ALT and AST liver function of mice decreased significantly.
[0096] Figure 6 It showed that after IPA treatment, the levels of serum inflammatory factors IL6 and TNFα in mice were significantly decreased.
[0097] Figure 7 RT-PCR detection showed that IPA alleviated the expression of inflammatory factor-related RNA levels in mice with acetaminophen-induced drug-induced liver injury.
[0098] Figure 8 The results of tunel staining of mice with acetaminophen-induced drug-induced liver injury were shown.
[0099] Fig. 9 Western Blot results showing that IPA alleviated acetaminophen-induced drug-induced liver injury in mice.
[0100] Fig.10 showed that IPA treatment could attenuate the severity of acetaminophen-induced liver injury at 72 h. DETAILED DESCRIPTION
[0101] After extensive and in-depth research, the inventor unexpectedly discovered for the first time that indolepropionic acid can effectively prevent and / or treat drug-induced liver injury. Experiments show that in the acetaminophen (APAP) mouse model and the d-galactosamine (GalN) / lipopolysaccharide (LPS) mouse model, indolepropionic acid inhibits the generation of NLRP3 inflammasomes, a key protein in the progression of liver injury, and has the effect of preventing drug-induced liver injury; in the acetaminophen (APAP) mouse model, indolepropionic acid reduces inflammatory infiltration and liver necrosis, inhibits the progression of liver injury to liver failure, and has the effect of treating drug-induced liver injury. On this basis, the inventor completed the present invention.
[0102] the term
[0103] As used herein, the terms "pharmaceutical composition of the present invention" and "drug of the present invention" are used interchangeably and refer to a preparation or pharmaceutical composition containing IPA, or a pharmaceutically acceptable salt thereof, or a derivative thereof as an active ingredient.
[0104] As used herein, the terms "preparation combination", "preparation combination of the present invention" and "drug of the present invention" are used interchangeably and all refer to the pharmaceutical composition or kit described in the first aspect of the present invention.
[0105] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".
[0106] As used herein, the term "subject", "subject in need" refers to any mammal or non-mammal. Mammals include, but are not limited to, humans, vertebrates such as rodents, non-human primates, cows, horses, dogs, cats, pigs, sheep, goats.
[0107] Drug-induced liver injury
[0108] Drug-induced liver injury refers to damage to the liver tissue structure or function caused by drugs. This damage may be temporary or permanent, and in severe cases may even lead to liver failure. The symptoms of drug-induced liver injury vary and may include jaundice, abdominal pain, fatigue, nausea, vomiting, loss of appetite, etc. Some common drugs, such as acetaminophen (Tylenol), aspirin, ibuprofen, etc., may cause liver damage, but the correlation between liver damage and drugs is the result of the combined effect of multiple factors.
[0109] In the present invention, the drug-induced liver injury includes acute liver injury caused by drug overdose and chronic liver injury caused by drug side effects.
[0110] Indolepropionic acid
[0111] Indole-3-propionic acid (IPA, molecular formula C 11 H 11 NO) is an important end product of tryptophan metabolism indole products. Indolepropionic acid is a plant growth regulator with auxin biological activity, mainly used as a pharmaceutical intermediate and plant growth stimulant.
[0112]
[0113] Tryptophan is an essential amino acid and the only amino acid in the human body that contains an indole structure. It is rich in oats, milk, yogurt, cheese, red meat, eggs, fish, etc. Tryptophan can be metabolized by intestinal flora to produce indole products, thereby regulating the body's homeostasis. In recent years, it has played an important regulatory role in intestinal and liver diseases. In addition, the instability of the intestinal microbiome and the increase in pathogen abundance are associated with increased susceptibility to a variety of metabolic liver diseases.
[0114] The present invention finds that indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof can inhibit the progression of liver necrosis in drug-induced liver injury, alleviate liver injury, and inhibit liver inflammation.
[0115] Pharmaceutical composition
[0116] The pharmaceutical composition provided by the present invention preferably contains 0.1-99 wt % of the first active ingredient, and the remainder is the second active ingredient, a pharmaceutically acceptable carrier, a diluent or a solution or a saline solution.
[0117] The first active ingredient of the present invention is indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof. In addition, it can also be used in combination with other therapeutic agents, that is, the second active ingredient.
[0118] The second active ingredient can be any drug ingredient that can prevent and / or treat drug-induced liver injury, including but not limited to statins, anti-tuberculosis drugs, traditional Chinese medicine, etc.
[0119] When necessary, one or more pharmaceutically acceptable carriers may be added to the drug of the present invention, including conventional diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants, etc. in the pharmaceutical field.
[0120] The compounds and pharmaceutical compositions provided by the present invention may be in various forms, such as tablets, injections, capsules, powders, syrups, solutions, suspensions and aerosols, and may be present in suitable solid or liquid carriers or diluents and in suitable sterile apparatus for injection or instillation.
[0121] The various dosage forms of the pharmaceutical composition of the present invention can be prepared according to conventional preparation methods in the pharmaceutical field. The unit dosage of the preparation formula generally contains 0.05-1000 mg of the active compound of the present invention, preferably, the unit dosage of the preparation formula contains 1 mg-500 mg of the active compound of the present invention.
[0122] The pharmaceutical composition of the present invention can be used clinically in mammals, including humans and animals, and can be administered through the mouth, nose, skin, lungs or gastrointestinal tract. Oral administration is the most preferred. The most preferred daily dose is 0.01-400 mg / kg body weight, taken at one time, or 0.01-200 mg / kg body weight taken in divided doses. Regardless of the method of administration, the optimal dose for an individual should be determined based on the specific treatment. Usually, a small dose is started and the dose is gradually increased until the most suitable dose is found.
[0123] The drugs or inhibitors of the present invention can be administered in various ways, for example, by injection, spraying, nasal drops, eye drops, penetration, absorption, physical or chemical mediated methods, such as introduction into the body into muscle, intradermal, subcutaneous, intravenous, mucosal tissue; or mixed or encapsulated in other substances and introduced into the body.
[0124] Typically, the active ingredient of the present invention or the pharmaceutical composition containing it can be administered in a unit dosage form, and the administration route can be enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs and respiratory tract, skin, vagina, rectum, etc.
[0125] The dosage form can be a liquid dosage form, a solid dosage form or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including O / W types, W / O types and multiple emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops, nasal drops, lotions and liniments, etc.; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.; semisolid dosage forms can be ointments, gels, pastes, etc.
[0126] The active ingredients of the present invention can be made into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.
[0127] In order to prepare the active ingredients of the present invention into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and glidants. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the adhesive may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.
[0128] The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.
[0129] In order to prepare the dosing unit into a capsule, the active ingredient of the present invention can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient can also be first made into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. The diluents, binders, wetting agents, disintegrants, and glidants used to prepare the tablets of the present invention can also be used to prepare the capsules of the present invention.
[0130] To prepare the active ingredient of the present invention into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and an appropriate amount of a solubilizer, a cosolvent, a pH adjuster, and an osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; the pH adjuster can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support agent.
[0131] Furthermore, if necessary, colorants, preservatives, perfumes, flavoring agents or other additives may be added to the pharmaceutical preparations.
[0132] The active ingredient or composition of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs.
[0133] When the active ingredient of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.
[0134] The main advantages of the present invention include:
[0135] The present invention provides the use of indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof in treating drug-induced liver injury, which has the following advantages:
[0136] (1) Indolepropionic acid is the final product of indole products in tryptophan metabolism and is safe and effective.
[0137] (2) Administration of indolepropionic acid can effectively reduce the RNA expression levels of IL1β, IL6, and TNFα, alleviate liver tissue inflammatory infiltration and liver necrosis, thereby reducing drug-induced liver injury and inhibiting the progression of liver failure.
[0138] (3) Administration of indolepropionic acid can inhibit the increase of autoimmune liver inflammation and has a protective effect on acute immune liver disease.
[0139] (4) The present invention provides a new method for treating drug-induced liver injury.
[0140] (5) The method of the present invention is simple to operate, simple to prepare the drug, and highly efficient.
[0141] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for which specific conditions are not indicated in the following examples are usually based on conventional conditions, such as the conditions described in Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts. Unless otherwise stated, materials and reagents used in the embodiments of the present invention are all commercially available products.
[0142] Example 1 Detection of IPA in Serum of Patients with Drug-Induced Liver Injury
[0143] 1.1 Clinical patient cohort
[0144] After review by the Ethics Committee of Shanghai Oriental Hospital and informed consent from the patients, this study included 11 patients with drug-induced liver injury who met the diagnostic criteria of the guidelines and were confirmed by medical history, serology, B-ultrasound and other imaging examinations; patients with autoimmune liver disease, viral hepatitis and other liver diseases were excluded.
[0145] 1.2 IPA detection method
[0146] After the peripheral venous blood collected from patients was placed at 4°C overnight, it was centrifuged at 4°C, 3000rpm, for 15 minutes the next day, and the supernatant was taken. Using the enzyme-linked biological human IPA Elisa detection kit (YJ986012), 10μl of serum was diluted to 50μl with sample diluent, incubated with horseradish peroxidase-labeled antibodies at 37°C for 1h, and then washed 5 times. 100μl of color development solution was added to each well, incubated at 37°C in the dark for 15min, and then 50μl of stop liquid was added. The IPA concentration was determined by reading the absorbance photometer at 450nm.
[0147] 1.3 Results
[0148] Clinical liver function data were collected, and serum IPA concentrations of patients with drug-induced liver disease were detected using Elisa kits.
[0149] Figure 1 The results showed that compared with the volunteers in the control group, the IPA concentration in the serum of patients with DILI (DILI) decreased, indicating that the serum content of IPA in patients with DILI had a downward trend. At the same time, the correlation analysis between the serum liver function of patients with DILI and IPA showed that the serum IPA content was significantly negatively correlated with ALT and AST; and had no significant relationship with the bilirubin content. The area under the diagnostic ROC curve was 0.808.
[0150] Example 2 Preventive Effect of IPA on Liver Damage
[0151] 2.1 Methods
[0152] 2.1.1 Modeling method
[0153] I) Acetaminophen (APAP) Model
[0154] C57BL / 6 mice were divided into two groups and acetaminophen (300 mg / kg, fasting for more than 16 hours, intraperitoneal injection for modeling). Two days before the start of modeling, IPA was dissolved in 5% CMC and gavaged at a concentration of 200 mg / kg to one group of the APAP modeling group (hereinafter referred to as the APAP+IPA group), and the control group was gavaged with 5% CMC (hereinafter referred to as the APAP group) daily. The mice were killed at 0h, 12h, 24h, and 48h. Blood was collected from the eye sockets, and the liver was exposed and completely removed. The right liver was embedded in paraffin, and the left liver was used for RNA and protein extraction for subsequent RT-PCR and Western blot verification.
[0155] The survival rate test modeling method was the same as before. The model group (n=15) and IPA treatment group (n=15) were used to model severe liver injury mice with a lethal dose of 500 mg / kg APAP. The treatment plan was the same as before, and the survival status was recorded every 1 hour.
[0156] II) d-Galactosamine (GalN) / lipopolysaccharide (LPS) model
[0157] C57BL / 6 mice were divided into two groups. After fasting for 12 hours, a single intraperitoneal injection of GalN 500 mg / kg was used, followed by an intraperitoneal injection of LPS 5 μg / kg for acute liver injury modeling. Two days before the start of modeling, IPA was dissolved in 5% CMC and gavaged at a concentration of 200 mg / kg to one group of the G / L modeling group (hereinafter referred to as the G / L+IPA group), and the control group was gavaged with 5% CMC (hereinafter referred to as the G / L group) daily. Mice were killed 4 hours after modeling, blood was collected from the eye sockets, and the liver was exposed and completely removed. The right liver was embedded in paraffin, and RNA and protein were extracted from the left liver for subsequent RT-PCR and Western blot verification.
[0158] 2.1.2 Liver gross injury results and HE staining
[0159] The mouse liver injury model was established by intraperitoneal injection of acetaminophen. Figure 4 A, CMC, IPA group), 12h, 24h, 48h modeling group ( Figure 4 A, CMC, IPA groups), five mice in each group.
[0160] 2.1.3 HE staining
[0161] The paraffin-embedded tissue was cut into 0.4 μm slices, and then dewaxed with xylene three times, each for 15 minutes. The dewaxed slices were hydrated with graded alcohol (100%, 95%, 85%, 75%, each for 3 minutes), washed three times with PBS, stained with hematoxylin for 1 minute, eosin for 30 seconds, washed three times with PBS, dried, and sealed with neutral resin.
[0162] 2.1.4 Liver function ALT and AST detection
[0163] The collected mouse blood was centrifuged using the above method to collect serum, which was then handed over to Wuhan Sewell Company for on-machine testing using fully automatic biochemical analysis.
[0164] 2.1.5 Detection of serum inflammatory factors IL6 and TNFα
[0165] Serum inflammatory factors were detected using the IL6 ELISA kit (Cat. No.: E-EL-M0044) and TNFα ELISA kit (Cat. No.: E-EL-M3063) of Elabscience. 10 μl of serum was diluted to 100 μl with sample diluent, incubated with biotinylated antibody at 37°C for 1 hour, and then washed 3 times. 100 ul of HRP enzyme conjugate working solution was added to each well, incubated at 37°C for 30 minutes, and washed 5 times. 90 μl of substrate solution was added to each well, incubated at 37°C in the dark for 15 minutes, and then 50 μl of stop liquid was added. The concentration of inflammatory factors was determined by reading the absorbance photometer at 450 nm.
[0166] 2.1.6 Real time-PCR (RT-PCR) detection of changes in inflammatory indicators in mouse liver
[0167] (1) RNA extraction
[0168] Add 1ml Trizol (RNAiso Plus) to the tissue and let it stand for 5 minutes, then blow it up with a pipette and collect it in an imported Eppendorf centrifuge tube. Add 0.2ml chloroform (one-fifth the volume of Trizol), cover tightly, and shake thoroughly for 15s until it is fully emulsified. Let it stand at room temperature for 5min (at this time, adjust the centrifuge to 4℃, 12,000g for preparation). Centrifuge at 4℃, 12000g for 15min. Take the upper transparent band, add 0.4ml isopropanol (the same volume as the supernatant sucked out from the top), mix it up and down slowly 5 times, and let it stand at room temperature for 10min. Centrifuge at 4℃, 12000g for 10min. When a precipitate is visible at the bottom, discard the supernatant.
[0169] Gently add 1 ml of 75% ethanol (prepared with DEPC water), flick up the RNA precipitate, rinse, centrifuge at 4°C and 7500g for 5 minutes, and aspirate the supernatant as thoroughly as possible to prevent the loss of RNA precipitate. Invert the EP tube to dry the water droplets on the tube wall, dissolve the dried RNA in 30 μl of DEPC water, measure the OD260 / 280 value with a spectrophotometer, prepare the working concentration (1 μg / μl), and detect the RNA integrity by 1% agarose gel electrophoresis, and store at -80°C for use.
[0170] (2) Reverse transcription reaction
[0171] Reverse transcription uses TAKARA kit, 10μl system reverses 1000ng RNA, taking the reverse 1ug, 20ul system as an example, take the reverse transcription kit reagents 1, 2, 3. Measure the concentration of each RNA and calculate the amount required for 1μg of RNA. Take a common eight-tube PCR tube and add the system: 5*Primescript PT Enzyme MIX (4ul), Total RNARNase Free dd H20 (make up to 20μl). Reverse transcription is performed on a common PCR instrument, 37℃ for 15 minutes, 85℃ for 30 seconds, and stored at 4℃.
[0172] (3) real time-PCR
[0173] Take a 1.5ml EP tube to make a MIX of 2*TB Green, primers, and ddH2O. 10ul system: 2*TB Green (5ul), primers (0.3ul each for forward and reverse), ddH2O (make up to 6ul). Dispense the MIX into the real-time plate, 6ul per well, and operate on ice.
[0174] Then add 4ul of the corresponding diluted template to each well and put it on the machine.
[0175] (4) Primer sequence
[0176] Table 1 shows the primer sequences used for RT-PCR.
[0177] Table 1
[0178]
[0179]
[0180] 2.1.7 Tunel staining
[0181] Dewax in xylene for 5-10 minutes. Replace with fresh xylene and dewax for another 5-10 minutes. Anhydrous ethanol for 5 minutes. 90% ethanol for 2 minutes. 70% ethanol for 2 minutes, distilled water for 2 minutes. Add 20μg / ml DNase-free proteinase K and incubate at 20-37℃ for 15 minutes. Add 50μl TUNEL detection solution to the sample and incubate at 37℃ in the dark for 60 minutes. Wash 3 times with PBS or HBSS. Seal the slide with anti-fluorescence quenching sealing solution and observe under a fluorescence microscope. The excitation wavelength range is 450nm.
[0182] 2.1.8 Western Blot detection of protein level changes of inflammasome markers in mouse liver
[0183] (1) Western Blot Steps
[0184] Lyse the tissue with RIPA and lyse on ice for 30 minutes. Centrifuge at 12000rpm, 4℃ for 5 minutes, take the supernatant for further BCA protein quantification, and after measuring the protein content, calculate the volume of the solution containing 20μg protein as the loading amount. After adding enough electrophoresis solution, start preparing for loading, the voltage is 80V, and adjust the voltage to 120V after bromophenol blue runs to the lower gel. Electrophoresis can be terminated when bromophenol blue just runs out, and transfer to the membrane. Use the wet transfer method, set a constant current of 300mA, and transfer can be completed in 75min. After the transfer is completed, move the membrane to a plate containing blocking solution (5% w / v skim milk) and shake on a decolorization shaker at room temperature for 1h. Dilute the primary antibody to an appropriate concentration with the primary antibody diluent; add the antibody solution dropwise to the antibody incubation box and incubate at 4℃ overnight. The next day, wash 3 times with 0.1% TBST (Tween20+TBS) on a decolorization shaker at room temperature, 10min each time. Prepare the secondary antibody dilution and contact the membrane. After incubation at room temperature for 1 hour, wash 3 times with TBST on a decolorizing shaker at room temperature for 10 minutes each time, and use ECL luminescent solution for color development. Table 2 shows the information of the antibodies used.
[0185] Table 2
[0186]
[0187] 2.2 Results
[0188] 2.2.1 Survival rate test
[0189] like Figure 2 As shown in the figure, the liver of mice in the APAP group had more obvious necrosis in general, and the degree of necrosis was reduced after IPA administration. The survival rate of mice in the IPA group was 66% (15 mice, no death within 24 hours), and the feeding condition was good within 24 hours. The survival rate of mice in the CMC control group was 40% (15 mice, 5 deaths within 24 hours) at 72 hours, and the feeding condition was poor.
[0190] Plotting the survival curve Figure 3 As shown, IPA has a protective effect on APAP-induced liver injury, and the difference is statistically significant (p=0.0247; IPA / CMC HR: 0.3391).
[0191] 2.2.2 HE staining results
[0192] Figure 4 As shown in A, after APAP modeling (compared with the group without modeling at 0h), the mouse liver showed obvious necrotic areas surrounding the central vein, and obvious inflammatory infiltration, while the IPA gavage group could significantly reduce the inflammatory infiltration caused by APAP modeling, and the necrotic area was significantly smaller than that of the modeling group at the same time point ( Figure 4 (middle B).
[0193] In the GalN / LPS model, it can be seen that the lysis and necrosis of liver cells in the model group (CMC) is more obvious, while the liver necrosis in the IPA group is milder ( Figure 4 Middle C).
[0194] 2.2.3 Liver function ALT and AST detection
[0195] like Figure 5 As shown in the figure, ALT and AST in the IPA gavage group were significantly lower than those in the APAP group, indicating that IPA can continue to play a protective role at 12h, 24h and 48h of acute inflammation.
[0196] 2.2.4 Detection of serum inflammatory factors IL6 and TNFα
[0197] like Figure 6 As shown in the figure, the levels of serum inflammatory factors in the IPA gavage group were significantly decreased, indicating that IPA can continue to play a role in reducing the level of inflammation at 12h, 24h and 48h of acute inflammation.
[0198] 2.2.5 Real time-PCR (RT-PCR) detection of changes in inflammatory indicators in mouse liver
[0199] RT-PCR experiments showed that the RNA levels of IL1β, IL6, TNFα, NLRP3 and Caspase1 in the APAP+IPA200 group were significantly decreased compared with those in the APAP group ( Figure 7 ), indicating that IPA has an in vivo inhibitory effect on inflammatory infiltration of drug-induced liver injury in mice.
[0200] 2.2.6 Tunel staining results
[0201] like Figure 8 As shown, after the use of IPA, there were fewer cells with positive TUNEL staining, indicating that IPA can prevent the apoptosis of liver cells in mice with drug-induced liver injury.
[0202] 2.2.7 Changes in protein levels of inflammasome markers in mouse liver
[0203] APAP intraperitoneal injection for 24 h successfully increased the expression of NLRP3 protein in the mouse liver, and this increase in NLRP3 protein level caused by APAP could be inhibited by IPA ( Fig. 9 ).
[0204] Therefore, IPA can significantly inhibit the production of NLRP3 inflammasome, a key protein in the progression of drug-induced liver injury in mice, thereby preventing liver damage.
[0205] The above results indicate that IPA can reduce inflammatory infiltration and the formation of inflammasomes in mice with drug-induced liver injury, thereby inhibiting the progression from liver injury to liver failure.
[0206] Example 3 IPA treatment of acetaminophen-induced liver injury in mice
[0207] 3.1 Modeling method
[0208] C57BL / 6 mice were modeled with acetaminophen (300 mg / kg, fasting for more than 16 hours, intraperitoneal injection). 2 hours after modeling, IPA was dissolved in 5% CMC and gavaged at a concentration of 200 mg / kg to one group of APAP modeling groups (hereinafter referred to as IPA+APAP group), and the control group was gavaged with 5% CMC (hereinafter referred to as APAP group) daily. Mice were killed 72 hours after modeling, blood was collected from the eye sockets, and the liver was exposed and completely removed. The right liver was embedded in paraffin.
[0209] The hepatotoxicity score was calculated according to the method described in S Suzuki 1, LH Toledo-Pereyra, FJ Rodriguez, DC Cejalvo. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation. 1993 Jun; 55(6): 1265-72. doi: 10.1097 / 00007890-199306000-00011. The liver injury scoring standard is as follows: 0 points for no injury; 1 point for minimal injury (affecting only a small number of hepatocytes); 2 points for mild injury (partial centrilobular necrosis, 1-2 rings of necrotic cells); 3 points for moderate injury (most of the centrilobular lobule necrosis, 2-3 rings of necrotic cells); 4 points for obvious injury (centrilobular necrosis of all lobules, 3-4 rings of necrotic cells); 5 points for severe injury (confluent necrosis of the entire lobule, 5 rings of necrotic cells and hemorrhage).
[0210] 3.2 Results
[0211] like Fig.10 As shown, the mouse liver injury model was established by intraperitoneal injection of acetaminophen. The mice in the IPA group had mild necrosis and good liver repair.
[0212] The above results indicate that IPA can reduce inflammatory infiltration and liver necrosis in mice with drug-induced liver injury, thereby inhibiting the progression of liver injury to liver failure.
[0213] discuss
[0214] In recent years, the tryptophan metabolic pathway is a related amino acid pathway that has been studied more in liver disease, and its metabolites are closely related to the progression of acute and chronic liver disease. In the study of Wang et al. (Indole-3-propionic acid alleviates sepsis-associated acute liver injury by activating pregnane X receptor, Mol Med. 2023 May 19; 29 (1): 65.), it was found that IPA alleviated sepsis-associated acute liver injury by activating pregnancy X receptor. In this study, Wang et al. used 20 mg / kg / d of IPA to effectively alleviate liver damage caused by sepsis. The present invention uses 200 mg / kg / d of IPA, which has a preventive and therapeutic effect on drug-induced liver injury liver disease. Different doses of IPA have different effects on liver diseases caused by different reasons.
[0215] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A use of an active ingredient, wherein the active ingredient is selected from indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof, characterized in that: For preparing a drug or a pharmaceutical composition or a kit for preventing and / or treating drug-induced liver injury; Wherein, the drug-induced liver injury is caused by drugs selected from the following group: acetaminophen, d-galactosamine, lipopolysaccharide, or a combination thereof.
2. The use according to claim 1, characterized in that The drug-induced liver injury is caused by drug overdose.
3. The use according to claim 1, characterized in that The drug-induced liver injury is caused by the side effects of drugs.
4. The use according to claim 1, characterized in that The drug-induced liver injury includes acute liver injury.
5. The use according to claim 1, characterized in that The dosage of the drug, pharmaceutical composition or kit is at least 200 mg / kg / d based on the dosage of IPA.
6. The use according to claim 1, characterized in that The drug or pharmaceutical composition or kit is also used for a purpose selected from the following group: (y1) reduce the levels of ALT and / or AST in the liver; (y2) reduce the level of pro-inflammatory factors; (y3) Reduce liver cell apoptosis.
7. The use according to claim 1, characterized in that The dosage form of the drug is an oral dosage form.
8. The use according to claim 1, characterized in that The pharmaceutical composition comprises: (z1) a first active ingredient, the first active ingredient comprising indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof; (z2) optionally, a second active ingredient, other drugs for preventing and / or treating drug-induced liver injury; and (z3) a pharmaceutically acceptable carrier.
9. A medicine box, characterized in that: The kit comprises: (a) a first active ingredient, the first active ingredient comprising indolepropionic acid, or a pharmaceutically acceptable salt thereof, or a derivative thereof; and (b) Drugs that cause drug-induced liver injury.
10. The medicine box according to claim 9, characterized in that The drug causing drug-induced liver injury is selected from the following group: acetaminophen, D-galactosamine, lipopolysaccharide, or a combination thereof.
Citation Information
Patent Citations
Application of indolepropionic acid in treatment of autoimmune liver injury and liver cirrhosis
CN117919232A
